Compare CXH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXH | ALXO |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 79.7M |
| IPO Year | N/A | 2020 |
| Metric | CXH | ALXO |
|---|---|---|
| Price | $7.94 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 25.9K | ★ 279.7K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.41 | $0.40 |
| 52 Week High | $7.74 | $2.27 |
| Indicator | CXH | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 50.89 |
| Support Level | $7.92 | $1.29 |
| Resistance Level | $8.00 | $1.56 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 16.67 | 51.09 |
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.